Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection.

COVID-19 SARS-CoV-2 antibody immunoassay nucleocapsid protein serological diagnostics time period

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
16 Oct 2021
Historique:
received: 17 08 2021
revised: 13 10 2021
accepted: 13 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1-3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection.

Identifiants

pubmed: 34679613
pii: diagnostics11101915
doi: 10.3390/diagnostics11101915
pmc: PMC8534661
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Surg. 2020 Jun;78:123-125
pubmed: 32360932
EBioMedicine. 2020 Sep;59:102915
pubmed: 32747185
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Geriatr Oncol. 2020 Sep;11(7):1187-1188
pubmed: 32467027
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
J Gen Virol. 2020 Aug;101(8):791-797
pubmed: 32430094
J Intern Med. 2021 Apr;289(4):559-573
pubmed: 33034095
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
J Clin Virol. 2020 Oct;131:104611
pubmed: 32882666
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183
Nat Commun. 2020 Nov 27;11(1):6044
pubmed: 33247152
Eur J Immunol. 2021 Mar;51(3):634-647
pubmed: 33251605
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
Viruses. 2021 Apr 30;13(5):
pubmed: 33946311
Diagnostics (Basel). 2021 Mar 25;11(4):
pubmed: 33806216
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Vaccines (Basel). 2020 May 14;8(2):
pubmed: 32423059
Front Immunol. 2020 Dec 16;11:610300
pubmed: 33391280
PLoS One. 2021 Jun 3;16(6):e0252628
pubmed: 34081747

Auteurs

Václav Šimánek (V)

Department of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Ladislav Pecen (L)

Department of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Hana Řezáčková (H)

Department of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Ondřej Topolčan (O)

Department of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Karel Fajfrlík (K)

Department of Microbiology, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Dalibor Sedláček (D)

Department of Infectious Diseases and Travel Medicine, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Robin Šín (R)

Department of Infectious Diseases and Travel Medicine, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.

Monika Bludovská (M)

Faculty of Medicine in Pilsen, Institute of Pharmacology and Toxicology, Charles University, 323 00 Pilsen, Czech Republic.

Petr Pazdiora (P)

Faculty of Medicine in Pilsen, Institute of Epidemiology, Charles University, 301 00 Pilsen, Czech Republic.

David Slouka (D)

Department of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, 309 55 Pilsen, Czech Republic.

Radek Kučera (R)

Department of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.
Faculty of Medicine in Pilsen, Institute of Pharmacology and Toxicology, Charles University, 323 00 Pilsen, Czech Republic.

Classifications MeSH